Woei-Cherng Shyu

This inventor holds 21 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Stem Cell Engineering. Top assignees: China Medical University, Academia Sinica, Industrial Technology Research Institute. Active years: 2008-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Woei-Cherng Shyu. Retrieved from https://idiyas.com/inventor/woei-cherng-shyu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 6)

% Patents Active = 76.2

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 10)

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Taipei, TW (2008 - 2022)
TaiChung, TW (2017 - 2023)

Company Filing History:

11 out of 110

China Medical University

Industrial Technology Research Institute

patents

4. 1 out of 21

China Medical University Hospital

The University of North Carolina at Chapel Hill

patents

where one patent can have more than one assignee

Years Active: 2008-2026

Loading Chart...

Areas of Expertise:

Gene-Engineered Stem Cells

Insulin Like Growth Factor

Induced Pluripotent Stem Cells

Mesenchymal Stem Cells

Cancer Therapy

Brain Tissue Damage

Olfactory Stem Cells

Neurodegenerative Diseases

Magnetic Separation

Erythropoietin

Granulocyte-Colony Stimulating Factor

Neurotrophic Factors

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12674141 - Gene-engineered mesenchymal stem cells and applications thereof (2026-07-07),

2. 12226437 - Method for enhancing expression of insulin like growth factor 1 receptor in umbilical cord mesenchymal stem cell expressing IGF1R and method for obtaining multipotent umbilical cord mesenchymal stem cell (2025-02-18),

3. 11760980 - Induced pluripotent stem cells (IPSCS) and applications thereof (2023-09-19),

4. 11529373 - Method for enhancing expression of insulin like growth factor 1 receptor in mesenchymal stem cell, method for obtaining mesenchymal stem cell, and method for treating brain tissue damage (2022-12-20),

5. 11458171 - Engineering stem cells for cancer therapy (2022-10-04),

6. 11318170 - Treatment of brain damage using umbilical cord blood cells (2022-05-03),

7. 11110129 - Method for treating multiple sclerosis (2021-09-07),

8. 10988733 - Methods for obtaining pluripotent adult olfactory stem cells from an olfactory mucosa tissue (2021-04-27),

9. 10736964 - Immunomagnetic nanocapsule and kit for treating cancer (2020-08-11),

10. 10696945 - Methods for treating a brain tissue damage by cultured adult pluripotent olfactory stem cells (2020-06-30),

11. 10660918 - Method for enhancing insulin like growth factor 1 receptor expression of mesenchymal stem cell, method for isolating mesenchymal stem cell, and use of mesenchymal stem cell (2020-05-26),

12. 10035791 - Bicyclic compound and pharmaceutical composition thereof for treating stroke and use thereof (2018-07-31),

13. 9718835 - [object Object] (2017-08-01),

14. 9540611 - Methods for treating and/or reversing neurodegenerative diseases and/or disorders (2017-01-10),

15. 8993342 - Magnetic separation unit, magnetic separation device and method for separating magnetic substance in bio-samples (2015-03-31),

Title: Woei-Cherng Shyu: Innovator in Stem Cell Research

Introduction

Woei-Cherng Shyu is a prominent inventor based in Taipei, Taiwan, recognized for his significant contributions to stem cell research. With a portfolio of 20 patents, his innovative work primarily focuses on enhancing therapies through advanced cellular techniques. His research has broad implications for regenerative medicine and biotechnology.

Latest Patents

Shyu's latest patents showcase groundbreaking methods in the field of stem cell enhancement and application. One notable patent outlines a technique for increasing the expression of the insulin-like growth factor 1 receptor (IGF1R) in umbilical cord mesenchymal stem cells. This method involves culturing the cells in a medium containing platelet-derived growth factor BB (PDGF-BB), which effectively enhances IGF1R expression. Another recent patent involves induced pluripotent stem cells (iPSCs), which includes methods for generating somatic cells capable of becoming iPS cells without oncogenic properties. This innovative approach holds promise for cell transplantation and cellular differentiation, thereby advancing stem cell applications.

Career Highlights

Throughout his career, Woei-Cherng Shyu has made substantial contributions to the scientific community, particularly in working with esteemed research institutions. He has been associated with China Medical University and Academia Sinica, where he collaborated on various research projects aimed at improving therapeutic strategies using stem cells.

Collaborations

Shyu has partnered with notable colleagues such as Chang-Hai Tsai and Chen-Huan Lin. These collaborations have further enriched the research landscape and facilitated the development of innovative techniques in stem cell biology. Together, they have contributed to advancing the understanding and application of mesenchymal stem cells for medical science.

Conclusion

Woei-Cherng Shyu exemplifies innovation in the growing field of stem cell research. His numerous patents and collaborative efforts are paving the way for future advancements that could transform treatments in regenerative medicine. As the healthcare landscape continues to evolve, Shyu's work remains at the forefront of this vital research area.

Profile summary based on public USPTO records.